The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 67, Issue 3, 2005, Pages 196-203

  Gallagher, A ^a   Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Insulin aspart; Lipids; Post prandial hyperglycaemia; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; ISOPHANE INSULIN; LIPID; NEUTRAL INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN METABOLISM; LIPID BLOOD LEVEL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 13844262952     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.07.010     Document Type: Article

References (30)

1. S.M. Haffner, R.A. Valdez, H.P. Hazuda, B.D. Mitchell, P.A. Morales, and M.P. Stern Prospective analysis of the insulin-resistance syndrome (syndrome X) Diabetes 41 1992 715 722
2. W.B. Kannel, R.B. D'Agostino, P.W. Wilson, A.J. Belanger, and D.R. Gagnon Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience Am. Heart J. 120 1990 672 676
3. O.P. Ganda, and C.F. Arkin Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes Diabetes Care 15 1992 1245 1250
4. J. Auwerx, R. Bouillon, D. Collen, and J. Geboers Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus Arteriosclerosis 8 1988 68 72
5. I. Juhan-Vague, C. Roul, M.C. Alessi, J.P. Ardissone, M. Heim, and P. Vague Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin Thromb Haemost 61 1989 370 373
6. E.K. Hoogeveen, P.J. Kostense, and P.J. Jeks Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study Arterioscler. Thromb. Vasc. Biol. 18 1998 133 138
7. M. Steiner, K.M. Reinhardt, B. Krammer, B. Ernst, and A.D. Blann Increased levels of soluble adhesion molecules in Type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control Thromb Haemost 72 1994 979 984
8. L. Cominacini, A. Fratta Pasini, and U. Garbin Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control Diabetologia 38 1995 1122 1124
9. M. Hanefeld, S. Fischer, and U. Julius Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up Diabetologia 39 1996 1577 1583
10. B. Balkau, E. Eschwege, and L. Papoz Risk factors for early death in non insulin dependent diabetes and men with known glucose tolerance status Br. Med. J. 307 1993 295 299
11. Anonymous, Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group, Lancet 354 (1999) 617-621.
12. J.H. Anderson, R.L. Brunelle, and V.A. Koivisto Reduction of post prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment Diabetes 46 1997 265 270
13. P.D. Home, A. Lindholm, B. Hylleberg, and P. Round Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in Type 1 diabetic patients Diabetes Care 21 1998 1904 1909
14. P. Raskin, R.A. Guthrie, L. Leiter, A. Riis, and L. Jovanovic Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with Type 1 diabetes Diabetes Care 23 2000 583 588
15. A. Lindholm, J. McEwen, and A.P. Riis Improved post-prandial glycaemic control with insulin aspart. A randomized double-blind cross-over trial in Type 1 diabetes Diabetes Care 22 1999 801 805
16. J.H. Anderson, R.L. Brunelle, V.A. Koivisto, M.E. Trautmann, L. Vignati, and R. DiMarchi Improved mealtime treatment of diabetes mellitus using an insulin analogue Clin. Ther. 19 1997 62 72
17. J.H. Anderson, R.L. Brunelle, P. Keohane, V.A. Koivisto, M.E. Trautmann, and L. Vignati Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus Arch. Intern. Med. 157 1997 1249 1255
18. M.N. Feinglos, C.H. Thacker, J. English, M.A. Bethel, and J.D. Lane Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with Type 2 diabetes Diabetes Care 20 1997 1539 1542
19. A.M. Rosenfalck, P. Thorsby, and L. Kjems Improved postprandial glycaemic control with insulin aspart in Type 2 diabetic patients treated with insulin Acta Diabetol. 37 2000 41 46
20. B.O. Boehm, P.D. Home, C. Behrend, N.M. Kamp, and A. Lindholm Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients Diabet. Med. 19 2002 393 399
21. P.D. Home, L. Barriocanal, and A. Lindholm Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers Eur. J. Clin. Pharmacol. 55 1999 199 203
22. S.R. Mudaliar, F.A. Lindberg, and M. Joyce Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy non diabetic subjects Diabetes Care 22 1999 1501 1506
23. L. Heinemann, T. Heise, L.N. Jorgensen, and A.A. Starke Action profile of the rapid acting insulin analogue: human insulin B28Asp Diabetic Med. 10 1993 535 539
24. M. Berger, and L. Heinemann Are presently available insulin analogues clinically beneficial? Diabetologia 40 Suppl. 2 1997 S91 S96
25. L. Heinemann, A.A.R. Starke, A. Hohmann, and M. Berger Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal Horm. Metab. Res. 10 Suppl. 26 1992 137 139
26. L. Heinemann Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabetic Med. 12 1995 449 450
27. I. Hanning, P.D. Home, and K.G. Alberti Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies Diabetologia 28 1985 831 835
28. J. Harrison, A.W. Hodson, A.W. Skillen, R. Stappenbeck, L. Agius, and K.G.M.M. Alberti Blood glucose, lactate, pyruvate, glycerol, 3-hydroxybutyrate, and acetoacetate measurements in man using a centrifugal analyser with fluorimetric attachment J. Chem. Clin. Biochem. 26 1988 141 146
29. M.R. Taskinen Hyperlipidaemia in diabetes D.J. Betteridge Clinical Endocrinology and Metabolism vol. 3 1990 Balliere Tindall London 743 775
30. J. Joven, E. Vilella, B. Costa, P.R. Turner, C. Richart, and L. Masana Concentrations of lipids and apolipoproteins in patients with clinically well-controlled insulin-dependent and non-insulin-dependent diabetes Clin. Chem. 35 1989 813 816